Sera Prognostics (SERA)

Sera’s best-known product is the PreTRM test, a blood test designed to assess the risk of spontaneous preterm birth in certain asymptomatic singleton pregnancies. Preterm birth is a major medical challenge because it is associated with infant morbidity, mortality, and significant healthcare costs. By providing risk information earlier in pregnancy, Sera aims to support care pathways that may include additional surveillance, patient education, and evidence-based management strategies.

The company operates as a diagnostics business rather than a drug developer, and its commercial success depends on clinical validation, physician adoption, reimbursement coverage, and integration into prenatal care. Sera’s platform combines biomarker discovery with predictive analytics, giving it a broader potential role in developing additional maternal-fetal health tests over time.

As a public company, Sera Prognostics represents exposure to the specialized diagnostics market within women’s health. Its business is built around the premise that better risk prediction can help address unmet needs in pregnancy care, particularly in areas where standard clinical factors alone do not fully identify patients at elevated risk.